Clovis Oncology's (CLVS) Price Target Raised to $50 at SunTrust Robinson
Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.
SunTrust Robinson Humphrey maintained a Buy rating on Clovis Oncology (NASDAQ: CLVS) and raised its price target to $50.00 (from $38.00).
Shares of Clovis Oncology closed at $38.36 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Downgrades MGM Growth Properties (MGP) to Hold
- Credit Suisse Downgrades NetApp (NTAP) to Underperform
- Mizuho Securities Raises Price Target on Francesca's (FRAN) Following 3Q Beat
Create E-mail Alert Related CategoriesAnalyst PT Change
Related EntitiesSunTrust Robinson Humphrey
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!